COMMUNIQUÉS West-GlobeNewswire

Ipsen présente les derniers résultats d'une étude de phase II sur la corabotase, première de sa classe, concernant les rides glabellaires, montrant une durée d'effet prolongée et un niveau de satisfaction constamment élevé chez les patients
16/05/2026
Les patients traités avec la corabotase ont présenté un délai d'action rapide de 0,84 jour et un pic d'effet statistiquement supérieur à celui du placebo À la semaine 24, 60,8 % des patients traités avec la corabotase [...]
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
16/05/2026
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo At Week 24, 60.8% of patients treated with corabotase experienced clinically significant [...]
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
16/05/2026
The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab [...]
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15/05/2026
CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
15/05/2026
Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world’s largest pre-college STEM competition TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 [...]
Range Impact Reports 1Q 2026 Financial Results
15/05/2026
CLEVELAND, OHIO, May 15, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mine properties [...]
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
15/05/2026
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer - Allarity has received a Notice of Allowance for new intellectual [...]
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
15/05/2026
Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world’s largest pre-college STEM competition TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 [...]
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
15/05/2026
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was represented at the [...]
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
15/05/2026
Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has received a [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
15/05/2026
ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company, the annual equity incentive awards granted to [...]
4DMT Announces New Employment Inducement Grants
15/05/2026
EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
15/05/2026
Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe with Commercial [...]
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
15/05/2026
Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world’s largest pre-college STEM competition. TARRYTOWN, N.Y. and WASHINGTON, May 15, [...]
Trading in GN Store Nord shares by board members, executives and associated persons
15/05/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
The Robotic Spine Institute of Las Vegas Announces Dr. Kornelis Poelstra’s Completion of 2,000 Robotic Spine Surgeries
15/05/2026
Las Vegas-based spine surgeon reaches milestone following 16 years of robotic-assisted procedures across multiple surgical platforms Dr. Kornelis Poelstra performing a robotic-assisted spine surgery at Southern Hills [...]
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
15/05/2026
- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer - - Appointed Jesper [...]
Solana Company Reports First Quarter 2026 Financial Results
15/05/2026
NEWTOWN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company, today announced results for the quarter ended March 31, 2026. First Quarter Recent [...]
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
15/05/2026
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific [...]

Pages